{
  "id": "c30ef117666a0251",
  "title": "Gene-edited CAR-T cells erase aggressive T-cell leukemia",
  "description": "A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely rewriting tiny sections of DNA, scientists at UCL and Great Ormond Street Hospital created universal CAR T-cells capable of targeting the cancer without harming themselves\u2014a long-standing challenge in T-cell\u2013based therapies. Early trial results show deep, long-lasting remissions, including in patients who had exhausted standard treatment options.",
  "content": "A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely rewriting tiny sections of DNA, scientists at UCL and Great Ormond Street Hospital created universal CAR T-cells capable of targeting the cancer without harming themselves\u2014a long-standing challenge in T-cell\u2013based therapies. Early trial results show deep, long-lasting remissions, including in patients who had exhausted standard treatment options.",
  "source": "Health & Medicine News -- ScienceDaily",
  "source_url": "https://www.sciencedaily.com/releases/2025/12/251211040438.htm",
  "published_at": "2025-12-11T09:14:40+00:00",
  "fetched_at": "2025-12-12T00:22:56.348095+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": null,
  "raw_data": {
    "title": "Gene-edited CAR-T cells erase aggressive T-cell leukemia",
    "description": "A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely rewriting tiny sections of DNA, scientists at UCL and Great Ormond Street Hospital created universal CAR T-cells capable of targeting the cancer without harming themselves\u2014a long-standing challenge in T-cell\u2013based therapies. Early trial results show deep, long-lasting remissions, including in patients who had exhausted standard treatment options.",
    "url": "https://www.sciencedaily.com/releases/2025/12/251211040438.htm",
    "published": "2025-12-11T09:14:40+00:00",
    "source": "Health & Medicine News -- ScienceDaily"
  }
}